Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review

被引：26
|
作者：
Diedhiou, Demba [1 ,2 ]
Cuny, Thomas [1 ]
Sarr, Anna [2 ]
Diop, Said Norou [2 ]
Klein, Marc [1 ]
Weryha, Georges [1 ]
机构：
[1] Lorraine Univ, Univ Hosp Ctr Nancy, Dept Endocrinol, Vandoeuvre Les Nancy, France
[2] Cheikh Anta Diop Univ, Univ Hosp Ctr Dakar, Dept Internal Med 2, Dakar, Senegal
来源：
ANNALES D ENDOCRINOLOGIE | 2015年 / 76卷 / 06期
关键词：
Osteoporosis; Denosumab; Fracture risk; Renal insufficiency; Safety; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS; TURNOVER MARKERS; RISK REDUCTION; FRACTURE RISK; ALENDRONATE; THERAPY; MASS; PHASE-2;
D O I：
10.1016/j.ando.2015.10.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Denosumab is an anti-RANK ligand (RANKL) monoclonal antibody approved for the treatment of postmenopausal osteoporosis and prevention of skeletal metastasis complications. Administered subcutaneously every 6 months, it reduces the risk of vertebral fracture by 70% and of hip fracture by 40%. Its safety profile is acceptable. Denosumab may be used to treat patients with moderate to severe renal insufficiency. It has anti-fracture activity equivalent to that of zoledronic acid, but no residual effect, and no action at all beyond 6 months. In France, denosumab is reimbursed as a second-line treatment after a first attempt with bisphosphonate. (C) 2015 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：650 / 657
页数：8
相关论文
共 50 条
  • [21] Efficacy and Safety of Denosumab on Osteoporosis in Kidney Transplant Recipients.
    Park, W.
    Kwon, J.
    Lim, J.
    Kim, Y.
    Paek, J.
    Jin, K.
    Han, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 676 - 676
  • [22] META-ANALYSIS OF EFFICACY AND SAFETY OF DENOSUMAB IN POSTMENOPAUSAL OSTEOPOROSIS
    Xuan, S.
    Ma, J.
    Liu, G. G.
    VALUE IN HEALTH, 2015, 18 (03) : A153 - A153
  • [23] Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety
    Gopaul, Aquila
    Kanagalingam, Tharsan
    Thain, Jenny
    Khan, Tayyab
    Cowan, Andrea
    Sultan, Nabil
    Clemens, Kristin K.
    ARCHIVES OF OSTEOPOROSIS, 2021, 16 (01)
  • [24] The Efficacy and Safety of Denosumab for Osteoporosis in Advanced CKD with or Without Dialysis
    Cho, Illeon
    An, Jung Nam
    Song, Young Rim
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 219 - 219
  • [25] Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis
    Julissa Serrano, Ana
    Begona, Leire
    Anitua, Eduardo
    Cobos, Raquel
    Orive, Gorka
    GYNECOLOGICAL ENDOCRINOLOGY, 2013, 29 (12) : 1005 - 1014
  • [26] SAFETY OF DENOSUMAB IN POST-MENOPAUSAL OSTEOPOROSIS AND IN CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Aubailly, M.
    Barnetche, T.
    Combe, B.
    Gaujoux-viala, C.
    Lukas, C.
    Morel, J.
    Che, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 701 - 702
  • [27] Risk for Infections During Treatment With Denosumab for Osteoporosis: A Systematic Review and Meta-analysis
    Diker-Cohen, Talia
    Rosenberg, Dana
    Avni, Tomer
    Shepshelovich, Daniel
    Tsvetov, Gloria
    Gafter-Gvili, Anat
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (05):
  • [28] Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
    Yanbeiy, Zeina A.
    Hansen, Karen E.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 2843 - 2852
  • [29] Efficacy and safety of denosumab treatment in a boy with cherubism
    Kawamura, Haruka
    Watanabe, Satoshi
    Takashi, I
    Asahina, Izumi
    Moriuchi, Hiroyuki
    Dateki, Sumito
    HORMONE RESEARCH IN PAEDIATRICS, 2019, 91 : 211 - 211
  • [30] Osteoporosis and CKD-MBD in hemodialysed patients: efficacy and safety of denosumab
    Bracaccia, Maria Elena
    Moioli, Alessandra
    Fofi, Claudia
    Mene, Paolo
    Festuccia, Francescaromana
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
12345